Relative Valuation Lab

Implied price gap for Eli Lilly And Company vs Novo Nordisk A/S

Live view of SEC fundamentals with peer-based benchmarks and implied valuation gaps.

Implied price

Blend averages both multiples when available.

Current vs implied

Current

$1,038.40

Implied

$29.50

If Eli Lilly And Company traded at Novo Nordisk A/S P/E multiple, the stock price would be $29.50 (vs $1,038.40).

-97.2% (-$1,008.90)

Implied from P/E

$29.50

Implied from P/S

$41.50

Implied price calculator

Apply the selected peer multiple to the target fundamentals.

Target company

LLY

Benchmark peer

NVO

Eli Lilly And Company fundamentals

Current price

$1,038.40

EPS (TTM)

11.71

Rev / share

47.50

Novo Nordisk A/S multiples

P/E multiple

2.52x

P/S multiple

0.87x

Growth vs value matrix

Bottom-right quadrant is the sweet spot: high growth, low valuation.

EV/Revenue vs growth

Smart diff metrics

Highlight the winner and flag when premiums are justified.

Metric	LLY	Delta vs NVO	NVO	Context
Revenue growth (LTM)	32.0%	27.8% higher	25.0%	Growth edge
Gross margin	81.3%	4.0% lower	84.7%	Pricing power
EBITDA margin	34.1%	3.5% lower	35.3%	Operating leverage
EV/Revenue	22.44x	1074.2% higher	1.91x	Multiple premium
P/E	88.21x	3401.0% higher	2.52x	Expensive
Net debt / EBITDA	2.0	30.8% lower	2.9	Lower leverage

Football field valuation

See where Eli Lilly And Company trades vs valuation ranges.

Peer implied

$28.14 - $54.69

Historical band

$929.67 - $1,136.27

DCF range

$688.25 - $931.16

Value trap detector

Quality signals that explain why a cheap stock might stay cheap.

Piotroski F-Score

Financial strength (0-9).

Eli Lilly And Company6/9

Partial coverage: 8/9 checks

Novo Nordisk A/S3/9

Partial coverage: 5/9 checks

Altman Z-Score

Bankruptcy risk gauge.

Eli Lilly And Company: not enough data yet.

Novo Nordisk A/S: not enough data yet.

Enterprise value bridge

Market cap + debt - cash = EV.

Enterprise value$1.0T

Market cap $979.4BDebt $34.6BCash -$3.4B

Risk factor diff (10-K Item 1A)

Unique risks that explain valuation discounts.

SEC text parsing is not configured yet. Connect 10-K text ingestion to compare Item 1A risk factors.

MD&A sentiment pulse

Tracks uncertainty language that often precedes multiple compression.

No MD&A sentiment data found. Enable the filing text analyzer to populate this chart.

LLY CIK: 59478

NVO CIK: 353278

Relative Valuation Lab

Implied price gap for Eli Lilly And Company vs Novo Nordisk A/S

Live view of SEC fundamentals with peer-based benchmarks and implied valuation gaps.

Implied price

Blend averages both multiples when available.

Current vs implied

Current

$1,038.40

Implied

$29.50

If Eli Lilly And Company traded at Novo Nordisk A/S P/E multiple, the stock price would be $29.50 (vs $1,038.40).

-97.2% (-$1,008.90)

Implied from P/E

$29.50

Implied from P/S

$41.50

Implied price calculator

Apply the selected peer multiple to the target fundamentals.

Target company

LLY

Benchmark peer

NVO

Eli Lilly And Company fundamentals

Current price

$1,038.40

EPS (TTM)

11.71

Rev / share

47.50

Novo Nordisk A/S multiples

P/E multiple

2.52x

P/S multiple

0.87x

Growth vs value matrix

Bottom-right quadrant is the sweet spot: high growth, low valuation.

EV/Revenue vs growth

Smart diff metrics

Highlight the winner and flag when premiums are justified.

Metric	LLY	Delta vs NVO	NVO	Context
Revenue growth (LTM)	32.0%	27.8% higher	25.0%	Growth edge
Gross margin	81.3%	4.0% lower	84.7%	Pricing power
EBITDA margin	34.1%	3.5% lower	35.3%	Operating leverage
EV/Revenue	22.44x	1074.2% higher	1.91x	Multiple premium
P/E	88.21x	3401.0% higher	2.52x	Expensive
Net debt / EBITDA	2.0	30.8% lower	2.9	Lower leverage

Football field valuation

See where Eli Lilly And Company trades vs valuation ranges.

Peer implied

$28.14 - $54.69

Historical band

$929.67 - $1,136.27

DCF range

$688.25 - $931.16

Value trap detector

Quality signals that explain why a cheap stock might stay cheap.

Piotroski F-Score

Financial strength (0-9).

Eli Lilly And Company6/9

Partial coverage: 8/9 checks

Novo Nordisk A/S3/9

Partial coverage: 5/9 checks

Altman Z-Score

Bankruptcy risk gauge.

Eli Lilly And Company: not enough data yet.

Novo Nordisk A/S: not enough data yet.

Enterprise value bridge

Market cap + debt - cash = EV.

Enterprise value$1.0T

Market cap $979.4BDebt $34.6BCash -$3.4B

Risk factor diff (10-K Item 1A)

Unique risks that explain valuation discounts.

SEC text parsing is not configured yet. Connect 10-K text ingestion to compare Item 1A risk factors.

MD&A sentiment pulse

Tracks uncertainty language that often precedes multiple compression.

No MD&A sentiment data found. Enable the filing text analyzer to populate this chart.

LLY CIK: 59478

NVO CIK: 353278